Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
100.2 USD | +0.05% |
|
+0.12% | +0.35% |
06-21 | Sector Update: Financial Stocks Slipping Late Afternoon | MT |
06-21 | US regulators single out four banks for flawed 'living wills' | RE |
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Ratings chart - Surperformance
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.35% | 564B | - | ||
+17.29% | 309B | C+ | ||
+18.32% | 255B | C+ | ||
+22.80% | 185B | B- | ||
+27.52% | 170B | B- | ||
+7.58% | 158B | C+ | ||
-2.54% | 152B | B- | ||
+5.99% | 146B | B- | ||
+14.20% | 142B | C+ | ||
+21.14% | 116B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JPM Stock
- CMCE Stock
- Ratings JPMorgan Chase & Co.